Global Hemoglobinopathies Market Report By Type (Thalassemia, Sickle Cell Disease, Other Hemoglobin (Hb) Variants,) By Diagnosis (Thalassemia, Sickle Cell Disease, Other Hemoglobin (Hb) Variants), By Therapy (Thalassemia, Sickle Cell Disease, Other Hemoglobin (Hb) Variants) And By Regions - Industry Trends, Size, Share, Growth, Estimation and Forecast, 2020-2027

ID:VMR11212374
April 2021
Report Formats:
Global Hemoglobinopathies Market Overview

The key driver impacting the hemoglobinopathies market is the huge prevalence of conditions such as thalassemia, sickle cell disease (SCD), and thalassemia. For instance, According to the World Health Organization, Haemoglobin disorders are considered the most critical health problem in 71% of 229 countries, and this 71% of countries include 89% of all births globally. Approximately 330 000 affected infants are born annually, in which 83% sickle cell disorders and 17% are affected by thalassaemias. The report published by the American Society of Hematology presents that there are over 95% of children born with thalassemia globally are from low- and middle-income countries, and less than 5% of children are born with thalassemia in the European and North America region. The presence of a strong product pipeline for the hemoglobinopathies treatment is also positively impacting the market growth. Moreover, the advancement in diagnostics and therapeutics and increased awareness about genetic testing for sickle cell anemia diagnosis contributes to the hemoglobinopathies market's growth in the coming years.
According to Value Market Research, the global hemoglobinopathies market size was valued at around USD 7000 million in 2020 and is estimated to grow at a CAGR of about 10.5% during the forecast period 2021 to 2027.

The increasing blood cancer cases among the population are estimated to augment hemoglobinopathies needs in the forecast period. For example, As per the Leukemia & Lymphoma Society, one person in the United States (US) is diagnosed with blood cancer every 3 minutes. Around 178,520 people are estimated to be diagnosed with lymphoma or myeloma and leukemia in 2020. In the U.S. leukemia, lymphoma, and myeloma new cases are anticipated to make up 9.9% of the estimated 1,806,590 new cancer cases diagnosed in 2020. However, the high treatment cost may hamper the market in the long run. Also, the lack of healthcare infrastructure negatively impacts the market. The current industry trends, such as the increasing R&D investment and initiatives to improve disease awareness levels, are likely to provide market players with new market opportunities.

The hemoglobinopathies market is vast, with many local and global players. The hemoglobinopathies market is extensive, with many international and regional players. The key market leaders follow several strategies to increase their market statuses, such as extending product portfolio, amalgamation, contracts, acquisitions, product upgrades to enlarge their market share across the globe. The important players studied in the report are Sangamo Therapeutics, Inc., bluebird bio, Inc., Pfizer, Inc., Prolong Pharmaceuticals LLC, Gamida Cell, Global Blood Therapeutics, Inc., Emmaus Life Sciences Inc., Novartis AG, and Bioverativ Inc.

Global Hemoglobinopathies Market Share

In this research report, the hemoglobinopathies market is segmented by type, diagnosis, therapy, and region.

Analysis by Type
By type, the report is categorized into Thalassemia, sickle cell disease, other hemoglobin (HB) variants. Sickle cell disease dominates the type segment with over 56.6% share in 2020. It is due to the growing initiatives by biopharmaceutical companies and nonprofit organizations focused on improving access to SCD treatment. Moreover, the growing prevalence of disease globally contributes to the growth of the sickle cell disease segment in the forecast period.

Analysis by Diagnosis
By diagnosis, the report is categorized into thalassemia, sickle cell disease, other hemoglobin (HB) variants. Sickle cell disease dominates the diagnosis segment with over 50% share in 2020. It is due to the high diagnostic rates in the North American region. Blood tests are majorly used for the  SCD diagnosis in patients. Moreover, introducing newborn baby screening programs for sickle cell disease in countries such as the U.S., France, and Italy is adding growth to this segment in the coming years.

Analysis by Therapy:
By therapy, the report is categorized into thalassemia, sickle cell disease, other hemoglobin (HB) variants. Sickle cell disease dominates the therapy segment with over 59.4% share in 2020. It is due to the extensive research that has been carried out to develop novel therapies for treating the disorder. Moreover, a strong product pipeline of gene therapy products, which includes HGB-206 (bluebird bio, Inc), CTX001 (CRISPR Therapeutics), and BIVV003 (Bioverativ Inc, and Sangamo Therapeutics, Inc. ) contributes to the increased market demand in the forecast period.

Analysis by Region:
In the regional outlook of the global Hemoglobinopathies market, the North America region dominates globally with a 35% market share in the forecast period. It is due to the increasing awareness of hemoglobinopathies among people and improving healthcare facilities. Research organizations and government bodies undertake various initiatives to promote research for developing novel therapies for treating hemoglobinopathies. For instance, The Sickle Cell Disease Coalition generates awareness, funds research programs, and offers access to treatment across the U.S.  Moreover, the presence of advanced diagnosis and treatment methods for common and rare genetic diseases, such as sickle cell disease and thalassemia, contribute to market growth across North America.
 
Market Segmentation covered in the Report:
By Type
  • Thalassemia
  • Sickle Cell Disease
  • Other Hemoglobin (Hb) Variants
 
By Diagnosis
  • Thalassemia (Blood Test, Genetic Test, Prenatal Genetic Test, Pre-implantation Genetic Diagnosis, Electrophoresis, Others)
  • Sickle Cell Disease (Blood Test, Genetic Test, Prenatal Genetic Test, Pre-implantation Genetic Diagnosis, Electrophoresis, Others)
  • Other Hemoglobin (Hb) Variants (Blood Test, Genetic Test, Prenatal Genetic Test, Pre-implantation Genetic Diagnosis, Electrophoresis, Others)
 
By Therapy
  • Thalassemia (Blood Transfusion, Iron Chelation Therapy, Bone Marrow Transplant, Others)
  • Sickle Cell Disease (Blood Transfusion, Hydroxyurea, Bone Marrow Transplant, Others)
  • Other Hemoglobin (Hb) Variants (Blood Transfusion, Hydroxyurea, Iron Chelation Therapy, Bone Marrow Transplant, Others)
 
By Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

METHODOLOGY

This market research report has been produced by gathering information on the basis of primary and secondary research. Secondary research has been done by using various sources which include (but not limited to) Company Websites, Paid Data Sources, Technical Journals, Financial Reports, SEC Filings, and other different industry publications. 

If specific information is required which is not currently within the scope of the report, it can be provided as a part of customization.   

1 . PREFACE
       1.1. Report Description
           1.1.1. Objective
           1.1.2. Target Audience
           1.1.3. Unique Selling Proposition (USP) & offerings
       1.2. Research Scope
       1.3. Research Methodology
           1.3.1. Market Research Process
           1.3.2. Market Research Methodology
 
2 . EXECUTIVE SUMMARY
       2.1. Highlights of Market
       2.2. Global Market Snapshot
 
3 . HEMOGLOBINOPATHIES – INDUSTRY ANALYSIS
       3.1. Introduction - Market Dynamics
       3.2. Market Drivers
       3.3. Market Restraints
       3.4. Opportunities
       3.5. Industry Trends
       3.6. Porter’s Five Force Analysis
       3.7. Market Attractiveness Analysis
           3.7.1 By Type
           3.7.2 By Diagnosis
           3.7.3 By Therapy
           3.7.4 By Region
 
4 . VALUE CHAIN ANALYSIS
       4.1. Value Chain Analysis
       4.2. Raw Material Analysis
           4.2.1. List of Raw Materials
           4.2.2. Raw Material Manufactures List
           4.2.3. Price Trend of Key Raw Materials
       4.3. List of Potential Buyers
       4.4. Marketing Channel
           4.4.1. Direct Marketing
           4.4.2. Indirect Marketing
           4.4.3. Marketing Channel Development Trend
 
5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK
       5.1. Impact Analysis of Covid-19 Outbreak
           5.1.1. Direct Impact on Production
           5.1.2. Supply Chain and Market Disruption
           5.1.3. Financial Impact on Firms and Financial Markets
       5.2. COVID-19 Impact Analysis by Production, Import, Export and Demand
       5.3. Market: Pre V/S Post COVID-19
       5.4. Estimated Impact of the Coronavirus (COVID-19) Epidemic
       5.5. COVID-19: Micro and Macro Factor Analysis
 
6 . GLOBAL HEMOGLOBINOPATHIES MARKET ANALYSIS BY TYPE
       6.1 Overview by Type
       6.2 Historical and Forecast Data
       6.3 Analysis by Type
       6.4 Thalassemia Market by Regions
       6.5 Sickle Cell Disease Market by Regions
       6.6 Other Hemoglobin (Hb) Variants Market by Regions
 
7 . GLOBAL HEMOGLOBINOPATHIES MARKET ANALYSIS BY DIAGNOSIS
       7.1 Overview by Diagnosis
       7.2 Historical and Forecast Data
       7.3 Analysis by Diagnosis
       7.4 Thalassemia Market by Regions
       7.5 Sickle Cell Disease Market by Regions
       7.6 Other Hemoglobin (Hb) Variants Market by Regions
 
8 . GLOBAL HEMOGLOBINOPATHIES MARKET ANALYSIS BY THERAPY
       8.1 Overview by Therapy
       8.2 Historical and Forecast Data
       8.3 Analysis by Therapy
       8.4 Thalassemia Market by Regions
       8.5 Sickle Cell Disease Market by Regions
       8.6 Other Hemoglobin (Hb) Variants Market by Regions
 
9 . GLOBAL HEMOGLOBINOPATHIES MARKET ANALYSIS BY GEOGRAPHY
       9.1. Regional Outlook
       9.2. Introduction
       9.3. North America
           9.3.1. Overview, Historic and Forecast Data
           9.3.2. North America By Segment
           9.3.3. North America By Country
           9.3.4. United State
           9.3.5. Canada
           9.3.6. Mexico
       9.4. Europe
           9.4.1. Overview, Historic and Forecast Data
           9.4.2. Europe by Segment
           9.4.3. Europe by Country
           9.4.4. United Kingdom
           9.4.5. France
           9.4.6. Germany
           9.4.7. Italy
           9.4.8. Russia
           9.4.9. Rest Of Europe
       9.5. Asia Pacific
           9.5.1. Overview, Historic and Forecast Data
           9.5.2. Asia Pacific by Segment
           9.5.3. Asia Pacific by Country
           9.5.4. China
           9.5.5. India
           9.5.6. Japan
           9.5.7. South Korea
           9.5.8. Australia
           9.5.9. Rest Of Asia Pacific
       9.6. Latin America
           9.6.1. Overview, Historic and Forecast Data
           9.6.2. Latin America by Segment
           9.6.3. Latin America by Country
           9.6.4. Brazil
           9.6.5. Argentina
           9.6.6. Peru
           9.6.7. Chile
           9.6.8. Rest of Latin America
       9.7. Middle East & Africa
           9.7.1. Overview, Historic and Forecast Data
           9.7.2. Middle East & Africa by Segment
           9.7.3. Middle East & Africa by Country
           9.7.4. Saudi Arabia
           9.7.5. UAE
           9.7.6. Israel
           9.7.7. South Africa
           9.7.8. Rest Of Middle East And Africa
 
10 . COMPETITIVE LANDSCAPE OF THE HEMOGLOBINOPATHIES COMPANIES
       10.1. Hemoglobinopathies Market Competition
       10.2. Partnership/Collaboration/Agreement
       10.3. Merger And Acquisitions
       10.4. New Product Launch
       10.5. Other Developments
 
11 . COMPANY PROFILES OF HEMOGLOBINOPATHIES INDUSTRY
       11.1. Company Share Analysis
       11.2. Market Concentration Rate
       11.3. Sangamo Therapeutics, Inc.
           11.3.1. Company Overview
           11.3.2. Financials
           11.3.3. Products
           11.3.4. Recent Developments
       11.4. bluebird bio, Inc.
           11.4.1. Company Overview
           11.4.2. Financials
           11.4.3. Products
           11.4.4. Recent Developments
       11.5. Pfizer, Inc.
           11.5.1. Company Overview
           11.5.2. Financials
           11.5.3. Products
           11.5.4. Recent Developments
       11.6. Prolong Pharmaceuticals LLC
           11.6.1. Company Overview
           11.6.2. Financials
           11.6.3. Products
           11.6.4. Recent Developments
       11.7. Gamida Cell
           11.7.1. Company Overview
           11.7.2. Financials
           11.7.3. Products
           11.7.4. Recent Developments
       11.8. Global Blood Therapeutics, Inc.
           11.8.1. Company Overview
           11.8.2. Financials
           11.8.3. Products
           11.8.4. Recent Developments
       11.9. Emmaus Life Sciences Inc.
           11.9.1. Company Overview
           11.9.2. Financials
           11.9.3. Products
           11.9.4. Recent Developments
       11.10. Novartis AG
           11.10.1. Company Overview
           11.10.2. Financials
           11.10.3. Products
           11.10.4. Recent Developments
       11.11. Bioverativ Inc.
           11.11.1. Company Overview
           11.11.2. Financials
           11.11.3. Products
           11.11.4. Recent Developments
 
 *Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies
 
LIST OF TABLES
 

  •  Market Snapshot
  •  Drivers : Impact Analysis
  •  Restraints : Impact Analysis
  •  List of Raw Material
  •  List of Raw Material Manufactures
  •  List of Potential Buyers
  •  COVID-19 Impact Analysis by Production, Import, Export and Demand
  •  Pre V/S Post COVID-19
  •  Estimated Impact Of The Coronavirus (Covid-19) Epidemic
  •  COVID-19: Micro and Macro Factor Analysis
  •  Analysis by Type (USD MN)
  •  Thalassemia Market by Geography (USD MN)
  •  Sickle Cell Disease Market by Geography (USD MN)
  •  Other Hemoglobin (Hb) Variants Market by Geography (USD MN)
  •  Analysis Market by Diagnosis (USD MN)
  •  Thalassemia Market by Geography (USD MN)
  •  Sickle Cell Disease Market by Geography (USD MN)
  •  Other Hemoglobin (Hb) Variants Market by Geography (USD MN)
  •  Analysis by Therapy (USD MN)
  •  Thalassemia Market by Geography (USD MN)
  •  Sickle Cell Disease Market by Geography (USD MN)
  •  Other Hemoglobin (Hb) Variants Market by Geography (USD MN)
  •  Global Hemoglobinopathies Market by Geography (USD MN)
  •  North America Market Analysis (USD MN)
  •  United State Market Analysis (USD MN)
  •  Canada Market Analysis (USD MN)
  •  Mexico Market Analysis (USD MN)
  •  Europe Market Analysis (USD MN)
  •  Europe Market Estimate by Country (USD MN)
  •  United Kingdom Market Analysis (USD MN)
  •  France Market Analysis (USD MN)
  •  Germany Market Analysis (USD MN)
  •  Italy Market Analysis (USD MN)
  •  Russia Market Analysis (USD MN)
  •  Spain Market Analysis (USD MN)
  •  Rest of Europe Market Analysis (USD MN)
  •  Asia Pacific Market Analysis (USD MN)
  •  China Market Analysis (USD MN)
  •  Japan Market Analysis (USD MN)
  •  India Market Analysis (USD MN)
  •  South Korea Market Analysis (USD MN)
  •  Australia Market Analysis (USD MN)
  •  Rest of Asia Pacific Market Analysis (USD MN)
  •  Latin America Market Analysis (USD MN)
  •  Brazil Market Analysis (USD MN)
  •  Argentina Market Analysis (USD MN)
  •  Peru Market Analysis (USD MN)
  •  Chile Market Analysis (USD MN)
  •  Rest of Latin America Market Analysis (USD MN)
  •  Middle East & Africa Market Analysis (USD MN)
  •  Saudi Arabia Market Analysis (USD MN)
  •  UAE Market Analysis (USD MN)
  •  Israel Market Analysis (USD MN)
  •  South Africa Market Analysis (USD MN)
  •  Rest of Middle East and Africa Market Analysis (USD MN)
  •  Partnership/Collaboration/Agreement
  •  Mergers And Acquisiton
 
 LIST OF FIGURES
 
  •  Research Scope of Hemoglobinopathies Report
  •  Market Research Process
  •  Market Research Methodology
  •  Global Hemoglobinopathies Market Size, by Region (USD MN)
  •  Porters Five Forces Analysis
  •  Market Attractiveness Analysis by Type
  •  Market Attractiveness Analysis by Diagnosis
  •  Market Attractiveness Analysis by Therapy
  •  Market Attractiveness Analysis by Region
  •  Value Chain Analysis
  •  Global Market Analysis by Type (USD MN)
  •  Thalassemia Market by Geography (USD MN)
  •  Sickle Cell Disease Market by Geography (USD MN)
  •  Other Hemoglobin (Hb) Variants Market by Geography (USD MN)
  •  Global Market Analysis by Diagnosis (USD MN)
  •  Thalassemia Market by Geography (USD MN)
  •  Sickle Cell Disease Market by Geography (USD MN)
  •  Other Hemoglobin (Hb) Variants Market by Geography (USD MN)
  •  Global Market Analysis by Therapy (USD MN)
  •  Thalassemia Market by Geography (USD MN)
  •  Sickle Cell Disease Market by Geography (USD MN)
  •  Other Hemoglobin (Hb) Variants Market by Geography (USD MN)
  •  Global Market by Revenue
  •  North America Market by Revenue
  •  Europe Market by Revenue
  •  Asia Pacific Market by Revenue
  •  Latin America Market by Revenue
  •  Middle East & Africa Market by Revenue
  •  Recent Development in Industry
  •  Company Market Share Analysis, 2020
 
 * Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.
 

Buy Chapters or Sections

Avail customized purchase options to meet your exact research needs:

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities

Objectives of Study

  • Define and measure the global market
  • Volume or revenue forecast of the global market and its various sub-segments with respect to main geographies
  • Analyze and identify major market trends along with the factors driving or inhibiting the market growth
  • Study the company profiles of the major market players with their market share
  • Analyze competitive developments

Why Choose Us

Client First Policy
Excellent Quality
Robust After Sales Support
24/7 Email Support

Clients

Testimonials